<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106045">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02109562</url>
  </required_header>
  <id_info>
    <org_study_id>RB-US-09-0010</org_study_id>
    <nct_id>NCT02109562</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind, Placebo Controlled, Multi-center Trial of Efficacy, Safety and Tolerability of RBP-7000 in Schizophrenia Patients</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 (90mg and 120mg) as a Treatment in Subjects With Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reckitt Benckiser Pharmaceuticals Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of RBP-7000 compared with
      placebo in the treatment of patients with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a double-blind, placebo-controlled, Phase III study with 90 mg and 120 mg doses
      of RBP-7000 compared with placebo over an 8-week treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>A change in Positive and Negative Syndrome Scale  (PANSS) Total Score at week 8 or early discontinuation of 113 participants</measure>
    <time_frame>Day 1 (Baseline), Week 8 or early discontinuation</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor judgement, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A change in the Clinical Global Impression - Severity of Illness (CGI-S) Scale at Week 8 or early termination of 113 participants</measure>
    <time_frame>Day 1 (Baseline), Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>The CGI-S rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to &quot;Normal, not at all ill&quot; and a rating of 7 is equivalent to &quot;Among the most extremely ill participants&quot;.  Higher scores indicating worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participants with Adverse Events</measure>
    <time_frame>Day 1 to week 8</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">339</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>RBP-7000 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBP-7000 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RBP-7000 administered as a 120 mg subcutaneous injection on Days 1 and 29 for a total of two injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered by subcutaneous injection on Days 1 and 29 for a total of two injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBP-7000</intervention_name>
    <description>Subcutaneous injection on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.  RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone.   The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner.</description>
    <arm_group_label>RBP-7000 90 mg</arm_group_label>
    <arm_group_label>RBP-7000 120 mg</arm_group_label>
    <other_name>Risperidone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Oral risperidone  0.25 mg tablets daily for the first two days of the screening period.  The two 0.25 mg tablets will help to confirm that study participants do not have any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).</description>
    <arm_group_label>RBP-7000 90 mg</arm_group_label>
    <arm_group_label>RBP-7000 120 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between the ages of 18 to 55 years, inclusive

          -  Diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual,
             Edition 4, text revision (DSM-IV-TR) criteria

          -  Subjects who are deemed &quot;valid&quot; by the State, Assessability, Face, Ecological, and
             Rule (SAFER) interview

          -  Subjects who are otherwise healthy on the basis of their physical examination

        Exclusion Criteria:

          -  Subjects who have an improvement in their total Positive and Negative Syndrome Scale
             (PANSS) score of 20% or greater between the initial screening visit and the first day
             of treatment.

          -  Subjects taking daily oral risperidone at a dose  â‰¥ 6 mg/day

          -  Subjects who have received a depot antipsychotic within 120 days of screen

          -  Subjects with treatment resistant schizophrenia, as judged by the investigator, who
             have been treated with antipsychotics for adequate durations and with adequate
             dosages.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Smith, BS</last_name>
    <role>Study Director</role>
    <affiliation>Reckitt Benckiser Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woodland International Research Group, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Aukstuolis, MD</last_name>
      <phone>501-944-6651</phone>
      <email>drjim@woodlandintlresearchgrp.com</email>
    </contact>
    <contact_backup>
      <last_name>Carol Witham</last_name>
      <phone>501 221 8651</phone>
      <email>carol@woodlandintlresearchgrp.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ashley Poole</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group, Inc.</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fayz Hudefi, MD</last_name>
      <phone>479-756-1460</phone>
      <email>drhudefi@woodlandintlresearchgrp.com</email>
    </contact>
    <contact_backup>
      <last_name>Carol Witham</last_name>
      <phone>501 944 6651</phone>
      <email>carol@woodlandintlresearchgrp.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Franchiseur</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Development - Cerritos, CA</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morteza Marandi, MD</last_name>
      <phone>562-246-3111</phone>
      <email>mmarandi@cnsmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lisa DeGabrielle</last_name>
      <phone>562 965 3466</phone>
      <email>ldegabrielle@cnsmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tyler Smith</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research of Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charmaine Semeniuk, MD</last_name>
      <phone>760-758-2222</phone>
      <email>semeniukc@synergyescondido.com</email>
    </contact>
    <contact_backup>
      <last_name>Woody Woodaman</last_name>
      <phone>619 778 7694</phone>
      <email>woodywoodaman@cox.net</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Manivanh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Networks, Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling, PhD</last_name>
      <phone>714-799-7799</phone>
      <email>davidwalling@cnstrial.com</email>
    </contact>
    <contact_backup>
      <last_name>Lill Le Hue</last_name>
      <phone>714 799 7799</phone>
      <email>lilyle@cnstrial.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Behavioral Research Specialists, LLC</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Carr, MD</last_name>
      <phone>888-255-5798</phone>
      <email>jessecarrmd@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Apostle Clinical Trials, Inc.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Volk, MD</last_name>
      <phone>562-437-4780</phone>
      <email>stephenvolk@apostleclinicaltrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Tim Zeleny</last_name>
      <phone>562 437 4780</phone>
      <email>timzeleny@apostleclinicaltrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kim Karen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ira Glick, MD</last_name>
      <phone>510-444-2877</phone>
      <email>iraglick@pacifictrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Shawna Cote</last_name>
      <phone>510 444 2877</phone>
      <email>shawnacote@pacifictrials.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Excell Research, Inc.</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Soefje, MD</last_name>
      <phone>760-758-2222</phone>
      <email>soefjemd@excellresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Carmalee Worsley</last_name>
      <phone>760 758 2222</phone>
      <email>cworsley@excellresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>So Nadia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CNRI- Los Angeles, LLC</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Manning, MD</last_name>
      <phone>562-928-8601</phone>
      <email>raymond.manning@cnrilallc.com</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Hua</last_name>
      <phone>562 928 8601</phone>
      <email>cnri@pacbell.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CNRI - San Diego, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tram Tran-Johnson, MD</last_name>
      <phone>619-481-5252</phone>
      <email>tranjohnson.cnri@pacbell.net</email>
    </contact>
    <contact_backup>
      <last_name>Robert Perkovic</last_name>
      <phone>619 481 5252</phone>
      <email>rperkovic.cnri@pacbell.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Zaglul, MD</last_name>
      <phone>407-644-1165</phone>
      <email>jzaglul@flcrc.com</email>
    </contact>
    <contact_backup>
      <last_name>Judy Zolna</last_name>
      <phone>407 644 1165</phone>
      <email>jzolna@flcrd.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rishi Kakar, MD</last_name>
      <phone>954-463-4321</phone>
      <email>rkakar@segalinstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Bonnie Segal, MD</last_name>
      <phone>305 722 8444</phone>
      <phone_ext>2260</phone_ext>
      <email>bsegal@segalinstitute.com</email>
    </contact_backup>
    <investigator>
      <last_name>Venus Thornhill</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Behavioral Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Lapeyra, MD</last_name>
      <phone>954-962-1355</phone>
      <email>olapeyra@segalinstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Bonnie Segal</last_name>
      <phone>605 722 8444</phone>
      <phone_ext>260</phone_ext>
      <email>bsegal@segalinstitute.com</email>
    </contact_backup>
    <investigator>
      <last_name>Denise Pichardo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Knapp, MD</last_name>
      <phone>407-644-1165</phone>
      <email>rknapp@flcrc.com</email>
    </contact>
    <contact_backup>
      <last_name>Ginny McClanahan</last_name>
      <phone>407 644 1165</phone>
      <email>gmcclanahan@flcrc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Beal</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Behavioral Health Hospital</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Lerman, MD</last_name>
      <phone>847-230-3599</phone>
      <email>mark.lerman@alexian.net</email>
    </contact>
    <contact_backup>
      <last_name>Karen Schmidt</last_name>
      <phone>847 230 3599</phone>
      <email>karen.schmidt@alexian.net</email>
    </contact_backup>
    <investigator>
      <last_name>Lisa Judge</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Via Christi Research</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Murphy, MD</last_name>
      <phone>316-291-7975</phone>
      <email>janie.krull@viachristi.org</email>
    </contact>
    <contact_backup>
      <last_name>Linda Brooks</last_name>
      <phone>316 868 8015</phone>
      <email>linda.brooks.@viachristi.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials, LLC</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kashinath Yadalam, MD</last_name>
      <phone>337-564-6405</phone>
      <email>yadalamk@msn.com</email>
    </contact>
    <contact_backup>
      <last_name>Peveto Kandyce</last_name>
      <phone>337 564 6405</phone>
      <email>kpeveto@lcct.us</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>J. Gary Booker, MD, APMC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104-2136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Booker, MD</last_name>
      <phone>318-227-9600</phone>
      <email>drjgarybooker@bellsouth.net</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Harrison, MD</last_name>
      <phone>318-227-9600</phone>
      <email>michellehigbmd@bellsouth.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Midwest Research Group</name>
      <address>
        <city>St Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Orf, MD</last_name>
      <phone>636-946-8032</phone>
      <email>Jorf@midwestresearchgroup.com</email>
    </contact>
    <contact_backup>
      <last_name>Jamie Orf</last_name>
      <phone>636 946 8032</phone>
      <email>Jorf@midwestresearchgroup.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>PsychCare Consultants Research</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohd Malik, MD</last_name>
      <phone>314-849-1853</phone>
      <email>pccresearch@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Syed Zaida</last_name>
      <phone>314 616 7071</phone>
      <email>pccresearch@aol.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricky Mofsen, MD</last_name>
      <phone>314-771-6387</phone>
      <email>rmofsen@slct.com</email>
    </contact>
    <contact_backup>
      <last_name>Andria Chastain</last_name>
      <phone>773 754 7981</phone>
      <email>achastain@slct.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Kunovac, MD</last_name>
      <phone>702-527-7401</phone>
      <email>kunovacmd@sbcglobal.net</email>
    </contact>
    <contact_backup>
      <last_name>Carmalee Worsley</last_name>
      <phone>760 758 2222</phone>
      <email>cworsley@excellresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jasmine Davis</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRI Lifetree</name>
      <address>
        <city>Marltron</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Krefetz, MD</last_name>
      <phone>856 334 6062</phone>
      <email>dkrefetz@crilifetree.com</email>
    </contact>
    <contact_backup>
      <last_name>Erica Ridolfi</last_name>
      <phone>856 334 6062</phone>
      <email>eridolfi@crilifetree.com</email>
    </contact_backup>
    <investigator>
      <last_name>Katrina Shukaitis</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurobehavioral Research, Inc.</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>11516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Brenner, MD</last_name>
      <phone>516-295-7230</phone>
      <email>rbrenner@nbrresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Monika Pawlowska</last_name>
      <phone>516 295 7230</phone>
      <email>mpawlowska@nbrresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Natalie Velez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Hope Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Semeko, MD</last_name>
      <phone>704-817-7732</phone>
      <email>semeko@newhcr.com</email>
    </contact>
    <contact_backup>
      <last_name>Tammy Rader</last_name>
      <phone>704 817 7732</phone>
      <email>rader@newhcr.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center, LLC</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette D'Souza</last_name>
      <phone>937-424-1050</phone>
      <email>bdsouza@midwestclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Robert Magrino</last_name>
      <phone>937 424 1050</phone>
      <email>rmagrino@midwestclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michelle Hall</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marvin Peyton, MD</last_name>
      <phone>405-753-4994</phone>
      <email>drpeyton@okcrc.net</email>
    </contact>
    <contact_backup>
      <last_name>Marvin L Peyton, MD</last_name>
      <phone>405 317 5783</phone>
      <email>drpeyton@okcrc.net</email>
    </contact_backup>
    <investigator>
      <last_name>Brooke Peyton</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRI Lifetree</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Gruener, MD</last_name>
      <phone>215-471-6859</phone>
      <email>dgruener@crilifetree.com</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Cassidy, MD</last_name>
      <phone>215 471 6859</phone>
      <email>mcassidy@crilifetree.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>FutureSearch Clinical Trials, L.P.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78734</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Garcia</last_name>
      <phone>512-380-9925</phone>
      <email>donaldg@fstrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Jesse Loudin</last_name>
      <phone>512 380 9925</phone>
      <email>jessel@fstrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hans Klein</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Brown</last_name>
      <phone>512-323-2622</phone>
      <email>david.brown@communityclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Janice Roggenkamp</last_name>
      <phone>713 665 8787</phone>
      <email>jroggenkamp@communityclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Diana Brewer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FutureSearch Clinical Trials, L.P.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Downing, MD</last_name>
      <phone>214-369-2600</phone>
      <email>michaeld@fstrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Annie Speno</last_name>
      <phone>916 934 0569</phone>
      <email>annie@btheodore.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Pillar Clinic Research, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Bartley, MD</last_name>
      <phone>214-396-4844</phone>
      <email>sbartley@pillarhc.com</email>
    </contact>
    <contact_backup>
      <last_name>Sophia Guerra</last_name>
      <phone>214-396-4844</phone>
      <email>sguerra@pillarhc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ann Tran</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bayou Clinical Research, Ltd</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Brams, MD</last_name>
      <phone>832-251-7000</phone>
      <email>drmattbrams@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Harpst, MD</last_name>
      <phone>832-251-7000</phone>
      <email>veritas@PDQ.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>March 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizophrenic</keyword>
  <keyword>Schizophrenias</keyword>
  <keyword>Risperidone</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
